Effect of single and combined drug treatments with Setanaxib and doxorubicin in vivo. (A,B) 2 × 106 GFP-expressing 32D FLT3-ITD cells were injected in C3H/HeJ mice via the tail vein, and respective drug treatments were applied. Setanaxib was given at 40 mg/kg body weight by daily gavage for 9 days, and doxorubicin at 3 mg/kg body weight by i.p. injection at day 3, 4, and 5 post-transplantation. Mice in independent experiments (two cohorts) were sacrificed 9- or 10-days post-transplantation. The percentage of GFP-positive cells was determined by flow cytometry in (A) BM and (B) spleen. (B,C) 5 × 105 GFP-expressing 32D FLT3-ITD cells were injected in C3H/HeJ mice and respective drug treatments were applied as in (A,B). Mice in independent experiments (two cohorts) were sacrificed 10 days post-transplantation. The percentage of GFP-positive cells was determined by flow cytometry in (C) BM and (D) spleen (n = 4–8 per group, mean ± SD). Statistical analyses were carried out using one-way ANOVA with Tukey´s post-test. (n.s.—not significant, * p < 0.05, ** p < 0.01, and *** p < 0.001).